Revolutionizing Cancer Treatment: LIfT BioSciences Secures $1.14M in Grant Round for Breakthrough Cell Therapy

LIfT BioSciences, a pioneering biotech company dedicated to advancing cancer therapies, has successfully raised $1,140,000 in a significant funding round aimed at accelerating the development of its groundbreaking alpha neutrophil cell therapy. The company's innovative approach, underpinned by its patented N-LIfT platform, harnesses the power of Immunomodulatory Alpha Neutrophils (IMANs) to effectively combat solid tumors. By transforming the tumor microenvironment and enlisting the entire immune system, LIfT's CAR-IMANs promise not only to attack tumors directly but also to foster lasting immunity and durable responses in patients. Founded by Alex Blyth in a deeply personal mission following the loss of his mother to pancreatic cancer, LIfT BioSciences is committed to changing the landscape of cancer treatment. The latest funding will facilitate the company’s efforts in initiating its much-anticipated Series A proof-of-concept clinical trial, as well as in negotiations with potential co-development partners for commercialization. With a focus on creating a diverse portfolio of CAR-IMAN therapies tailored for various solid tumors, LIfT aims to achieve complete remission for cancer patients before the decade concludes. As they forge partnerships with pharmaceutical companies, LIfT is poised to redefine the therapeutic potential of immunotherapy in oncology. For more information about LIfT BioSciences and their cutting-edge approaches, visit www.liftbiosciences.com.